Baseline drug Resistance Mutations are Detectable in HCV Genes NS3 and NS5A but not NS5B in Acute and Chronic HIV-Coinfected Patients

Plaza Z, Soriano V, Vispo E, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17: 921–926.

Leggewie M. , Sreenu V.B. , Abdelrahman T. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS 2013; 27: 2485–2488.

Webster D.P. , Wojcikiewicz T. , Keller M. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS 2013; 24: 179–183.

Fierer D.S. , Dieterich D.T. , Mullen M.P. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58: 873–879.

Sulkowski M.S. , Sherman K.E. , Dieterich D.T. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86–96.

Sulkowski M. , Pol S. , Mallolas J. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled Phase 2 trial. Lancet Infect Dis 2013; 13: 597–605.

Lawitz E. , Gane E.J. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369: 678–679.

Belda O. , Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res 2012; 170: 1–14.

Kowdley K.V. , Lawitz E. , Poordad F. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 222–232.

Franco S. , Casadellà M. , Noguera-Julian M. No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV/HIV-1 coinfected patients using deep sequencing. J Clin Virol 2013; 58: 726–729.

Palanisamy N. , Danielsson A. , Kokkula C. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013; 99: 12–17.

Fridell R.A. , Wang C. , Sun J-H Genotype and phenotypic analysis of variants resistant to hepatitis C virus non-structural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924–1935.

Bartels D.J. , Zhou Y. , Zhang E.Z. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800–807.

Treviño A. , de Mendoza C. , Parra P. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther 2011; 16: 413–416.

Bartels D.J. , Sullivan J.C. , Zhang E.Z. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAA) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544–1553.